Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach.

Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach.
复制标题

渗透性核壳聚合物植入物,用于使用微创鼻贮库(MIND)方法在CNS中持续递送BDNF AntagoNAT。

DOI:
10.1016/j.biomaterials.2021.120989
复制
发表时间:
2021-09
期刊:
影响因子:
14
通讯作者:
Amiji MM
Amiji MM
中科院分区:
工程技术1区
文献类型:
--
作者:
Padmakumar S;Jones G;Khorkova O;Hsiao J;Kim J;Bleier BS;Amiji MM

文献摘要

参考文献

相似文献

以微创方式直接向中枢神经系统(CNS)有效地给药的药物递送策略的发展仍然是阻碍生物疾病修饰疗法临床翻译的主要障碍。微创鼻腔给药(Mind)是一种新的直接鼻腔给药方法,通过直接给药到啮齿动物模型的嗅黏膜下间隙,成功地提供了高中枢神经系统的摄取和血脑屏障(BBB)药物的脑分布。本研究描述了定制植入物的工程设计,该工程具有一种独特的结构,即包裹治疗性药物的“渗透活性核心”和“可生物降解的聚合物外壳”,以实现使用Mind程序的长效递送。脑源性神经营养因子(BDNF)的脑源性神经营养因子(BDNF)拮抗剂在SD大鼠体内的中枢神经系统持续输送长达4周,导致多个脑组织内源性BDNF蛋白表达显著上调。这种核壳植入物的生物相容性,再加上它们实质性的药代动力学优势和Mind程序的安全性,突显了这种协同方法在治疗慢性年龄相关性神经退行性疾病方面的实用价值和翻译潜力。
The development of drug delivery strategies for efficacious therapeutic administration directly into the central nervous system (CNS) in a minimally invasive manner remains a major obstacle hindering the clinical translation of biological disease-modifying therapeutics. A novel direct trans-nasal delivery method, termed ‘Minimally-Invasive Nasal Depot’ (MIND), has proved to be successful in providing high CNS uptake and brain distribution of blood-brain barrier (BBB) impermeant therapeutics via direct administration to the olfactory submucosal space in a rodent model. The present study describes the engineering of custom-made implants with a unique architecture of an “osmotically-active core” entrapping the therapeutic and a “biodegradable polymeric shell” to enable long-acting delivery using the MIND procedure. The MIND-administered implant provided sustained CNS delivery of brain derived neurotrophic factor (BDNF) AntagoNATs for up to 4 weeks in Sprague Dawley rats resulting in significant endogenous BDNF protein upregulation in several brain tissues. The biocompatibility of such core-shell implants coupled with their substantial pharmacokinetic advantages and safety of the MIND procedure highlights the practical utility and translational potential of this synergistic approach for treatment of chronic age-related neurodegenerative diseases.
DOI: 10.3390/pharmaceutics10030116
发表时间: 2018-08-03
期刊: Pharmaceutics
影响因子: 5.4
作者:
Gänger S;Schindowski K
通讯作者: Schindowski K
DOI: 10.1080/01926230600713475
发表时间: 2006-01-01
影响因子: 1.5
作者:
Harkema, Jack R.;Carey, Stephan A.;Wagner, James G.
通讯作者: Wagner, James G.
鼻内递送绕过靶向治疗剂到中枢神经系统并治疗神经退行性疾病的血脑屏障。
DOI: 10.1186/1471-2202-9-s3-s5
发表时间: 2008-12-10
期刊: BMC neuroscience
影响因子: 2.4
作者:
Hanson LR;Frey WH 2nd
通讯作者: Frey WH 2nd
DOI: 10.1159/000007918
发表时间: 1998-01-01
期刊: EUROPEAN NEUROLOGY
影响因子: 2.4
作者:
Dingemanse, J;Kleinbloesem, CH;Gasser, UE
通讯作者: Gasser, UE
DOI: 10.1016/s0142-9612(03)00212-6
发表时间: 2003-09-01
期刊: BIOMATERIALS
影响因子: 14
作者:
Iwasaki, Y;Yamasaki, A;Ishihara, K
通讯作者: Ishihara, K